Targeted therapy combined with immunotherapy vs trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer

Table 4 Propensity score-adjusted multivariable Cox regression analysis of prognostic factors associated with progression-free survival in the original cohort, mean ± SD/n (%)

Dependent: Survival (PFS/30, status PFS)		All	HR (multivariable)
Gender	Male	80 (63.0)
	Female	47 (37.0)	0.99 (0.62-1.58, P = 0.969)
Age	≤ 60	51 (40.2)
	> 60	76 (59.8)	0.95 (0.62-1.47, P = 0.834)
ECOG	0-1	110 (86.6)
	2	17 (13.4)	0.51 (0.26-1.00, P = 0.051)
Number of metastatic organs	1	28 (22.0)
	≥ 2	99 (78.0)	2.40 (1.31-4.41, P = 0.005)
Primary tumor location	Right colon	31 (24.4)
	Left colon and rectum	96 (75.6)	1.23 (0.72-2.10, P = 0.450)
Liver metastasis	No	48 (37.8)
	Yes	79 (62.2)	0.91 (0.56-1.49, P = 0.721)
Lung metastasis	No	47 (37.0)
	Yes	80 (63.0)	0.99 (0.64-1.56, P = 0.982)
RAS	Wild-type	34 (26.8)
	Mutation	69 (54.3)	0.81 (0.50-1.34, P = 0.415)
	Unknown	24 (18.9)	0.67 (0.34-1.29, P = 0.228)
Treatment regimen	Targeted drug + PD-1	88 (69.3)
	TAS-102 + bevacizumab	39 (30.7)	1.26 (0.76-2.10, P = 0.367)
PS		0.3 ± 0.2	0.85 (0.23-3.18, P = 0.805)

n = 127, events = 100, likelihood ratio test = 19.13 on 11 (P = 0.059). HR: Hazard ratio; ECOG: Eastern Cooperative Oncology Group; PD-1: Programmed cell death 1; PFS: Progression-free survival; TAS-102: Trifluridine/tipiracil; PS: Propensity score.